This finding provides a novel insights and clinical application on ferroptosis, illustrating STEAP3 supplemented with PD-L2 as the potential therapeutic targets and predictive biomarker for cirrhotic HCC. Here, PDCD1LG2 is linked to hepatocellular carcinoma.